Version 1
: Received: 22 October 2024 / Approved: 23 October 2024 / Online: 24 October 2024 (04:36:33 CEST)
How to cite:
Gadaleta-Caldarola, G.; Lanotte, L.; Santoro, A. N.; Pinto, A.; Gadaleta-Caldarola, A.; Giacomelli, L.; Fedele, P. Predictive Factors of Antibody Drug Conjugates (ADCs) Treatment in Metastatic Breast Cancer: A Narrative Review. Preprints2024, 2024101831. https://doi.org/10.20944/preprints202410.1831.v1
Gadaleta-Caldarola, G.; Lanotte, L.; Santoro, A. N.; Pinto, A.; Gadaleta-Caldarola, A.; Giacomelli, L.; Fedele, P. Predictive Factors of Antibody Drug Conjugates (ADCs) Treatment in Metastatic Breast Cancer: A Narrative Review. Preprints 2024, 2024101831. https://doi.org/10.20944/preprints202410.1831.v1
Gadaleta-Caldarola, G.; Lanotte, L.; Santoro, A. N.; Pinto, A.; Gadaleta-Caldarola, A.; Giacomelli, L.; Fedele, P. Predictive Factors of Antibody Drug Conjugates (ADCs) Treatment in Metastatic Breast Cancer: A Narrative Review. Preprints2024, 2024101831. https://doi.org/10.20944/preprints202410.1831.v1
APA Style
Gadaleta-Caldarola, G., Lanotte, L., Santoro, A. N., Pinto, A., Gadaleta-Caldarola, A., Giacomelli, L., & Fedele, P. (2024). Predictive Factors of Antibody Drug Conjugates (ADCs) Treatment in Metastatic Breast Cancer: A Narrative Review. Preprints. https://doi.org/10.20944/preprints202410.1831.v1
Chicago/Turabian Style
Gadaleta-Caldarola, G., Luca Giacomelli and Palma Fedele. 2024 "Predictive Factors of Antibody Drug Conjugates (ADCs) Treatment in Metastatic Breast Cancer: A Narrative Review" Preprints. https://doi.org/10.20944/preprints202410.1831.v1
Abstract
Antibody-drug conjugates (ADCs) have revolutionized the treatment landscape for metastatic breast cancer (MBC), offering targeted delivery of cytotoxic agents with improved efficacy and tolerability compared to conventional chemotherapy. This narrative review explores key predictive factors influencing the efficacy of ADCs, focusing on HER2-targeted therapies such as trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd), as well as sacituzumab govitecan for triple-negative breast cancer (TNBC). HER2 expression, TROP-2 levels, hormone receptor (HR) status, and the tumor microenvironment emerge as critical biomarkers for patient selection and therapeutic outcomes. Additionally, we discuss resistance mechanisms, such as antigen loss, impaired drug internalization, and the role of circulating tumor DNA (ctDNA) in predicting ADC response. Finally, future perspectives on the sequential use of ADCs and potential combination therapies are highlighted, along with emerging agents targeting alternative antigens like HER3 and LIV-1. Overall, identifying predictive biomarkers and overcoming resistance mechanisms are essential for optimizing the use of ADCs in MBC, thereby improving patient outcomes.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
